Prospective Translational Study Investigating Predictors of Outcome in Metastatic Renal Cell Carcinoma Patients Treated With Nivolumab (I-Rene Trial)

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Status: Unknown

Conditions: Metastatic Renal Cell Carcinoma

Study type: Observational

Funder types: Other

Identifiers

NCT04891055

INT 71/18

Details and patient eligibility

About

Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)

Full description

Prospective translational study investigating predictors of outcome in metastatic renal cell carcinoma patients treated with Nivolumab (I-Rene trial)

Enrollment: 90 estimated patients

Sex: All

Ages: 18 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Written informed consent
• metastatic renal cell carcinoma (a clear-cell/ not clear-cell)
• Progression to previous treatment with tyrosine kinase inhibitors
• Patients candidates for II-line therapy with Nivolumab (or tyrosine kinase inhibitors-in the control arm)

Exclusion criteria

none

Trial design

90 participants in 2 patient groups

patients treated with nivolumab

Description:

Patients candidates for II line therapy with Nivolumab from clinical practice

patients treated with TKI

Description:

Patients candidates for II line therapy with TKI from clinical practice